GRAND RAPIDS — In raising an additional $4.28 million in venture capital funding,Tetra Discovery Partners LLCplans to support the ongoing clinical trials for a new drug to treat Alzheimer’s disease.
The Grand Rapids- and Kalamazoo-based Tetra Discovery Partners netted the funding as part of a $7.27 million Series A venture round that CEO Mark Gurney expects will successfully conclude within the next three months.
“We’re confident we’ll complete this round,” Gurney said.
Tetra Discovery Partners recently provided an update on the fundraising round and equity offering through a filing to the U.S. Securities and Exchange Commission. The amount raised so far came from nine investors, according to the filing. Lead investors includeApjohn Ventures LLC in Kalamazoo and Holland-basedGrand Angels, Gurney said.